Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
6750 participants
OBSERVATIONAL
2012-04-30
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The first phase of ACSIKS is an 18-month observational study involving 11 eye hospitals in 8 Asian countries; these hospitals manage more than 6700 cases of corneal infections every year. From the first quarter of 2012, all patients with a corneal infection will be recruited and a standard ACSIKS protocol will be applied; this protocol includes the use of a common set of study forms and a suggested panel of microbiological examinations. However, each centre will be continue to treat their patients with the anti-infective therapy standard for their centre. Data will be recorded for each patient for a period of six months, including their medical and surgical management, the final clinical outcome and vision.
Bacterial and fungal growths from patients will also be stored for further research during a second phase of ACSIKS. These studies will focus on evaluating the resistance of the most common bacterial infections to the current available antibiotics, performing DNA testing to compare our strains with bacterial infections in the West, and to developing new diagnostic tests and anti-infective therapies tailored to corneal infections in Asia.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients with an initial clinical diagnosis of infectious keratitis will be referred by the attending ophthalmologist-in-charge to an ACSIKS co-investigator or trial coordinator for recruitment into the study. Patients will be enrolled in the study after study informed consent is obtained and a trained interviewer will administer a standardized ACSIKS Clinical Case Report Form to each recruited subject. Information that will be documented would include the demographic profile (e.g. age, gender, ethnic group, occupation, etc), risk factors for infectious keratitis, presenting symptoms and prior treatment.
Patients who are contact lens wearers will also complete a separate contact lens questionnaire, with specific questions on duration of contact lens wear, type of contact lens and solutions used, lens wear schedule and habits, and adherence to lens care practices.
All patients will undergo a thorough ocular examination by the ophthalmologist-in-charge or an ACSIKS co-investigator, and details of the infectious keratitis and associated findings documented on the ACSIKS Clinical CRF. With the approval of the ophthalmologist-in-charge, corneal scrapings will then be collected as per the ACSIKS Microbiological Protocol. Each study subject will consequently still be managed by the ophthalmologist-in-charge according to his/her current clinical approach, with appropriate medical or surgical treatment carried out in accordance with the practice patterns and standards of his/her institution, and no attempt to deviate from current treatment practices.
Regular chart reviews will be performed by ACSIKS trial coordinators for the six months duration of the subjects' involvement to document the initial differential diagnoses and medical treatment, the microbiological results, and any changes to the diagnosis and treatment. The last consultation with the ophthalmologist-in-charge during that six month-period will be taken as the final study review.
Summary of the ACSIKS Microbiological Protocol:
At the discretion of the ophthalmologist-in-charge, corneal scrapings will be collected based on a list of investigations suggested by the ACSIKS Group.
All microbiological specimens will be incubated, interpreted and reported according to agreed upon common standards, regardless of the number of colonies present. Bacterial organisms will also be tested using standardized antibiograms agreed upon by microbiologists from the various participating institutions. Results of any and all microbiological testing will be collected and recorded into the ACSIKS Microbiological Case Report Form.
If these samples do yield a positive growth of either fungal or bacterial organisms (or both), the causative organisms cultured will be sub-cultured and stored at each site's ACSIKS freezer, for subsequent transport to the ACSIKS Central Repository in Singapore for use in future microbial studies under Phase 2 of the ACSIKS project.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Singapore Clinical Research Institute
OTHER
Asia Cornea Society
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof Donald TH Tan
Principal Investigator and Chairman, ACSIKS Council
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Donald TH Tan, FRCS(G)
Role: PRINCIPAL_INVESTIGATOR
Singapore National Eye Centre, Singapore Eye Research Institute, National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shandong Eye Institute
Qingdao, , China
Xiamen Eye Center
Xiamen, , China
L.V.Prasad Eye Institute
Hyderabad, Andhra Pradesh, India
Aravind Eye Hospital
Madurai, Tamil Nadu, India
Department of Ophthalmology, Faculty of Medicine, Osaka University Graduate School of Medicine Hospital
Osaka, , Japan
Department of Ophthalmology, Tottori University Hospital
Tottori, , Japan
Department of Ophthalmology and Visual Sciences, Philippine General Hospital
Manila, , Philippines
Singapore Eye Research Institute
Singapore, , Singapore
Department of Opthalmology & Visual Science, The Catholic University of Korea, Seoul St. Mary's Eye Institute
Seoul, , South Korea
Department of Opthalmology, National Taiwan University Hospital
Taipei, , Taiwan
Department of Ophthalmology, Faculty of Medicine, Siriraj Hospital, Mahidol University
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lixin Xie, MD
Role: primary
Li Wei
Role: primary
Prashant Garg
Role: primary
Sean D'Silva
Role: primary
Takeshi Soma
Role: primary
Chizu Touge
Role: primary
Denise Mae Palmos
Role: primary
Abriena Xie
Role: primary
Choun-Ki Joo
Role: primary
Stephanie Chu
Role: primary
Pormsiri Chinawangwatarnakrnl
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACSIKS
Identifier Type: -
Identifier Source: org_study_id